|Item||Catalog #||Description||Quantity||Price (USD)|
|Plasmid||58880||Plasmid sent as bacteria in agar stab||1||$65|
Virus (100 µL at titer ≥ 7×10¹² vg/mL)
and Plasmid. More Information
This material is available to academics and nonprofits only.
- Backbone size w/o insert (bp) 4698
- Total vector size (bp) 6360
Vector typeMammalian Expression, AAV
Growth in Bacteria
Growth Strain(s)NEB Stable
Growth instructionsStbl3 at 30C (use carbenicillin if using Stbl3) OR DH5a at 37C
Copy numberLow Copy
Alt namechannelrhodopsin-2 H134R mutant
Insert Size (bp)1662
- Promoter Syn
/ Fusion Protein
- GFP (C terminal on insert)
- Cloning method Restriction Enzyme
- 5′ cloning site BamHI (not destroyed)
- 3′ cloning site EcoRI (not destroyed)
- 5′ sequencing primer CTGCGTATGAGTGCAAG
- 3′ sequencing primer cagcgtatccacatagcg (Common Sequencing Primers)
Terms and Licenses
Plasmid is completely sequenced by the depositing lab. Multiple digestions were done to verify the vector structure. The construct and the virus were both tested in vitro.
Information for AAV Retrograde (Catalog # 58880-AAVrg) ( Back to top )
Ready-to-use AAV Retrograde particles produced from pAAV-Syn-ChR2(H134R)-GFP (#58880). In addition to the viral particles, you will also receive purified pAAV-Syn-ChR2(H134R)-GFP plasmid DNA.Humanized channelrhodopsin H134R mutant fused to GFP, under the control of the Synapsin promoter. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.
- Volume 100 µL
- Titer ≥ 7×10¹² vg/mL
- Pricing $350 USD for preparation of 100 µL virus + $30 USD for plasmid.
- Storage Store at -80℃. Thaw just before use and keep on ice.
- Shipment Viral particles are shipped frozen on dry ice. Plasmid DNA (≥ 200ng) will also be included in the shipment.
Viral Production & Use
- Packaging Plasmids encode adenoviral helper sequences and AAV rep gene
AAV retrograde cap gene
rAAV2-retro helper (plasmid #81070)
- Buffer PBS + 0.001% Pluronic F-68 + 200 mM NaCl
- Serotype AAVrg rAAV2-retro helper (plasmid #81070)
- Purification Iodixanol gradient ultracentrifugation
- Reporter Gene GFP
Requestor is responsible for compliance with their institution's biosafety regulations. Lentivirus is generally considered BSL-2. AAV is generally considered BSL-1, but may require BSL-2 handling depending on the insert. Biosafety Guide
Viral Quality Control
- Real-time qPCR: The number of genome copies in viral preparations was measured by SYBR green real-time qPCR with primers targeting the ITR. Titer values were deduced by comparing the genomic content of the viral preparation to a standard curve of a plasmid of known concentration. Read our AAV Titration by qPCR protocol here.
- Purity of viral preparation: Viral preparations were subjected to polyacrylamide gel electrophoresis (PAGE) followed by silver staining and the molecular weight and relative intensity of the viral capsid proteins was analyzed. The abundance of viral capsid proteins as a fraction of total protein present in the sample was used to determine purity of the AAV preparation.
- PCR confirmation of viral genome: PCR was carried out on the viral preparation with primers that amplify the transgene. The PCR products were visualized on an agarose gel for size confirmation.
Syn For: CAAGCACCCAACCCCCATTCCC
ChR2-H134R Rev: TGACCTACGGTGGAGCCATA
Visit our viral production page for more information.
Addgene CommentsRetrograde functionality is dependent on high viral titers. Addgene recommends not diluting your AAV preps prior to use.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
For your Materials & Methods section:pAAV-Syn-ChR2(H134R)-GFP was a gift from Edward Boyden (Addgene plasmid # 58880)
For your References section:Millisecond-timescale, genetically targeted optical control of neural activity. Boyden ES, Zhang F, Bamberg E, Nagel G, Deisseroth K. Nat Neurosci. 2005 Sep . 8(9):1263-8. 10.1038/nn1525 PubMed 16116447